A Randomized Phase II Trial of Dasatinib plus Abiraterone Compared to Abiraterone Alone for Metastatic, Castration-Resistant Prostate Cancer Prior to Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 12 Jul 2017
At a glance
- Drugs Dasatinib (Primary) ; Abiraterone; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- 05 Jul 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
- 10 Jun 2017 Biomarkers information updated
- 18 Feb 2017 Status changed from active, no longer recruiting to discontinued due to lack of funding as per the results published at the 2017 Genitourinary Cancers Symposium.